| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | fingolimod (Gilenya®) |
| Formulation | 0.5 mg capsule |
| Reference number | 2528 |
| Indication | Single disease modifying therapy in highly active relapsing remitting multiple sclerosis for patients with high disease activity despite treatment with at least one disease modifying therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/07/2014 |
| NICE guidance | TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |